CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

Nov 10, 2020

MUNICH, Germany, Nov. 10, 2020 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round. The financing was led by Vesalius Biocapital III and joined by Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors Forbion and BioGeneration Ventures. Representatives from Vesalius Biocapital III, NVF and Wachstumsfonds Bayern will join the Board.